NCT04625179

Brief Summary

melatonin proved an ability to repair bone defects and enhance osseointegration of dental implants. Also, hyaluronic acid has osteopromoting properties. the effect of melatonin and hyaluronic acid on the newly formed bone in maxillary sinus augmentation was evaluated

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
16

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Dec 2019

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 3, 2019

Completed
11 months until next milestone

First Submitted

Initial submission to the registry

November 6, 2020

Completed
6 days until next milestone

First Posted

Study publicly available on registry

November 12, 2020

Completed
25 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 7, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 7, 2020

Completed
Last Updated

December 17, 2020

Status Verified

December 1, 2020

Enrollment Period

1 year

First QC Date

November 6, 2020

Last Update Submit

December 15, 2020

Conditions

Outcome Measures

Primary Outcomes (4)

  • change Implant stability

    The result is presented as an ISQ value of 1-100. The acceptable stability range lies between 55-85 ISQ. The higher the ISQ, the more stable the implant

    at baseline and 6 months

  • change in bone density

    radiographical evaluation using CBCT

    at baseline, 1 month and 6 months

  • change in vertical bone height

    radiographical evaluation using CBCT

    at baseline, 1 month and 6 months

  • change in marginal bone level

    radiographical evaluation using CBCT

    at baseline, 1 month and 6 months

Secondary Outcomes (2)

  • Postoperative pain

    after 1 week

  • Postoperative swelling

    after 1 week

Study Arms (2)

Melatonin and hyaluronic acid and sinus membrane elevation

EXPERIMENTAL

melatonin and hyaluronic acid will be placed after maxillary sinus membrane elevation and simultaneous dental implants placement

Other: Melatonin and hyaluronic acid and sinus membrane elevation

sinus membrane elevation without any materials

ACTIVE COMPARATOR

no materials will be placed after maxillary sinus membrane elevation and simultaneous dental implants.

Procedure: sinus membrane elevation without any materials

Interventions

3 mg melatonin powder mixed with 0.2% hyaluronic acid gel will be placed to fill the sinus space and around the implant apex.

Melatonin and hyaluronic acid and sinus membrane elevation

No materials will be placed at the sinus space.

sinus membrane elevation without any materials

Eligibility Criteria

Age30 Years - 50 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Age range will be between (30 - 50) years old.
  • Patients with missed one or more of posterior teeth with minimum residual bone height 5 mm
  • Adequate inter-occlusal space of at least 8 mm

You may not qualify if:

  • Maxillary sinus diseases.
  • Previous sinus surgery like the Caldwell-Luc operation.
  • History of chemotherapy or radiotherapy to maxilla.
  • Presence of Underwood's septa/severe sinus floor convolutions.
  • Systemic disease affecting bone metabolism.
  • Uncontrolled diabetes mellitus.
  • Heavy smokers.
  • Para functional habits.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Faculty of Dentistry, Alexandria University

Alexandria, Egypt

Location

MeSH Terms

Conditions

Mouth, EdentulousAtrophy

Interventions

MelatoninHyaluronic Acid

Condition Hierarchy (Ancestors)

Mouth DiseasesStomatognathic DiseasesTooth DiseasesPathological Conditions, AnatomicalPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

TryptaminesIndolesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic CompoundsHormonesHormones, Hormone Substitutes, and Hormone AntagonistsGlycosaminoglycansPolysaccharidesCarbohydrates

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Assistant lecturer of DPH and Clinical statistician

Study Record Dates

First Submitted

November 6, 2020

First Posted

November 12, 2020

Study Start

December 3, 2019

Primary Completion

December 7, 2020

Study Completion

December 7, 2020

Last Updated

December 17, 2020

Record last verified: 2020-12

Locations